報價延遲最少15分鐘:2025/01/11 11:21 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-11.67/-6.65
|
|
企業價值
68.39M
|
| 資產負債 |
|
每股賬面淨值
1.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:21 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. |